[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging

• Published in: Acta neuropathologica 2017-10, Vol.134 (4), p.619-628
• Main Authors: Marquié, Marta, Siao Tick Chong, Michael, Antón-Fernández, Alejandro, Verwer, Eline E., Sáez-Calveras, Nil, Meltzer, Avery C., Ramanan, Prianca, Amaral, Ana C., Gonzalez, Jose, Normandin, Marc D., Frosch, Matthew P., Gómez-Isla, Teresa
• Format: Article
• Language: English
• Subjects: Advertising executives; Alzheimer's disease; Autoradiography; Biochemical analysis; Brain; Cognitive ability; Cortex (entorhinal); Cortex (temporal); Dementia disorders; Enzyme-linked immunosorbent assay; Medical research; Medicine; Medicine & Public Health; Neurodegenerative diseases; Neurofibrillary tangles; Neuroimaging; Neurosciences; Original Paper; Pathology; Positron emission tomography; Substantia alba; Superior temporal sulcus; Tau protein; Visual cortex
• ISSN: 0001-6322; 1432-0533
• DOI: 10.1007/s00401-017-1740-8

[F-18]-AV-1451, a PET tracer specifically developed to detect brain neurofibrillary tau pathology, has the potential to facilitate accurate diagnosis of Alzheimer’s disease (AD), staging of brain tau burden and monitoring disease progression. Recent PET studies show that patients with mild cognitive impairment and AD dementia exhibit significantly higher in vivo [F-18]-AV-1451 retention than cognitively normal controls. Importantly, PET patterns of [F-18]-AV-1451 correlate well with disease severity and seem to match the predicted topographic Braak staging of neurofibrillary tangles (NFTs) in AD, although this awaits confirmation. We studied the correlation of autoradiographic binding patterns of [F-18]-AV-1451 and the stereotypical spatiotemporal pattern of progression of NFTs using legacy postmortem brain samples representing different Braak NFT stages (I-VI). We performed [F-18]-AV-1451 phosphor-screen autoradiography and quantitative tau measurements (stereologically based NFT counts and biochemical analysis of tau pathology) in three brain regions (entorhinal cortex, superior temporal sulcus and visual cortex) in a total of 22 cases: low Braak (I–II, n  = 6), intermediate Braak (III–IV, n  = 7) and high Braak (V–VI, n  = 9). Strong and selective [F-18]-AV-1451 binding was detected in all tangle-containing regions matching precisely the observed pattern of PHF-tau immunostaining across the different Braak stages. As expected, no signal was detected in the white matter or other non-tangle containing regions. Quantification of [F-18]-AV-1451 binding was very significantly correlated with the number of NFTs present in each brain region and with the total tau and phospho-tau content as reported by Western blot and ELISA. [F-18]-AV-1451 is a promising biomarker for in vivo quantification of brain tau burden in AD. Neuroimaging–pathologic studies conducted on postmortem material from individuals imaged while alive are now needed to confirm these observations.